Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
- Durable anti-cancer activity was observed during monotherapy dose escalation without dose-limiting toxicities
- Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete regression observed in two of three metastatic lesions in the liver in response to single-agent MDNA11
- Immune pharmacodynamic data continues to support a differentiated mechanism with preferential expansion of potent cancer-fighting immune cells
- The monotherapy Recommended Dose for Expansion was established at 90g/kg administered every 2 weeks
TORONTO and HOUSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced a clinical update on the monotherapy dose escalation portion of the first-in-human, Phase 1/2 ABILITY Study in patients with advanced solid tumors, as its drug candidate MDNA11, a beta-only, long-acting IL-2 super-agonist, advances to the monotherapy dose expansion phase.
"We are pleased to see that MDNA11 continues to demonstrate durable single-agent activity in patients with advanced, treatment-refractory cancer, together with a manageable safety profile, and preserving its differentiated pharmacodynamic (PD) qualities, even though the Phase 1 ABILITY Study was not specifically designed to demonstrate efficacy," said Fahar Merchant, Ph.D., President and CEO of Medicenna. "The promising therapeutic activity observed in patients who have progressed on multiple prior anti-cancer therapies, including a patient with a particularly aggressive form of cancer – pancreatic ductal adenocarcinoma - fuels our enthusiasm for initiating the dose expansion phase of the study. The PD data supports 90g/kg dose as the Recommended Dose for Expansion (RDE), which will be evaluated in selected cancers that are most likely to benefit from MDNA11 monotherapy. We look forward to the upcoming readouts from the monotherapy dose expansion phase later this year and commencing the combination portion of the trial, where MDNA11 will be evaluated with KEYTRUDA®, as part of our clinical collaboration with Merck."
The main objectives of the dose escalation stage of the Phase 1/2 ABILITY study were to evaluate MDNA11's safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD), and preliminary anti-tumor activity to inform RDE selection in patients with advanced cancers that were refractory to up to 4 different lines of systemic therapy. A total of six dose escalation cohorts (MDNA11 dose ranging from 3g/Kg to 120 g/Kg) constituting 20 patients were evaluated, with the majority (75%) having also received at least one line of immunotherapy.
Key findings from the dose escalation portion of the study include:
Medicenna expects to report initial results from ABILITY's monotherapy dose expansion in the fourth quarter of 2023. Plans are to commence the combination phase of the trial evaluating MDNA11 with Keytruda in the fourth quarter of 2023, with initial results expected in early 2024.
About the Phase 1/2 ABILITY Study
The ABILITY (A Beta-only IL-2 ImmunoTherapY) study is designed to assess the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of various doses of intravenously administered MDNA11 in patients with advanced, treatment-refractory solid tumors. The trial includes an MDNA11 monotherapy phase, as well as a combination phase designed to evaluate MDNA11 with KEYTRUDA® (pembrolizumab). Approximately 104 patients are expected to be enrolled into the ABILITY Study. Following establishment of the RDE in the study's monotherapy dose escalation phase, Medicenna plans to conduct a dose expansion phase that will enroll patients with melanoma and other selected solid tumor types in the monotherapy and combination settings. For more information, see ClinicalTrials.gov Identifier: NCT05086692.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.